Pulsed-dye laser and XXXX delay progression of oral squamous cell carcinoma: a @entity19 model.

@entity309 @entity5 @entity19 @entity1544 @entity1968
OBJECTIVES/HYPOTHESIS: This study examined the role of the pulsed-dye laser (PDL) at 585 nm coupled with @entity1968 at therapeutic (5.0 mg/kg) and nontherapeutic (0.5 mg/kg) doses to delay the progression of @entity5 with a two-hit approach. The existing vasculature is selectively targeted by the laser, whereas @entity1968 inhibits future angiogenesis. STUDY DESIGN: Randomized, prospective study in a @entity19 model. METHODS: Twenty-five athymic @entity19 were inoculated with oral @entity1544 on six flank sites and randomly divided into five groups: 1) control subjects, 2) treatment with 0.5 mg/kg @entity1968 ( @entity309 0.5), 3) treatment with 5.0 mg/kg @entity1968 ( @entity309 5.0), 4) treatment with @entity309 0.5 + PDL, and 5) treatment with @entity309 5.0 + PDL. The PDL groups received irradiation after inoculation. The @entity1968 was administered daily. The @entity5 were counted and measured for 14 days. RESULTS: The control group developed visible @entity5 in 50% of the inoculation sites at 3 days compared with 3 days ( @entity309 0.5) and 4 days ( @entity309 5.0) for the @entity1968 groups and 9 days ( @entity309 0.5 + PDL) and 10 days ( @entity309 5.0 + PDL) for the laser treatment groups. There was no @entity5 growth until day 7 in the @entity309 5.0 + PDL group. The @entity5 volume was statistically different between the treatment groups. CONCLUSION: This study demonstrated the superiority of a single treatment with the PDL coupled with @entity1968 to delay the progression of @entity5 when compared with treatment with @entity1968 alone, thus introducing a novel strategy in @entity5 control.
